Bevacizumab

• A study of patients with colorectal cancer that have a genetic abnormality in the BRAF gene taking encorafenib plus cetuximab with or withou… Ended
  2023-509405-77-00 Phase III 13 countries Pfizer Inc.
• Tocotrienol and bevacizumab in metastatic colorectal cancer. A randomized phase II marker trial Ended
  2024-517075-21-00 Phase II 1 country Lillebaelt Hospital
• A randomized, 2-arm non-comparative phase II study on the efficacy of atezolizumab and Roche bevacizumab (Atezo/Bev) followed by on-demand s… Ended
  2024-512682-14-00 Phase II 1 country Klinikum der Universitaet Muenchen AöR
• Phase III randomized clinical trial for stage III epithelial ovarian cancer randomizing between primary cytoreductive surgery with or withou… Ended
  2023-509049-11-00 Phase III 7 countries Het Nederlands Kanker Instituut-Antoni van Leeuwenhoek Ziekenhuis Stichting
• A Study of Atezolizumab (Anti-PD-L1 Antibody) plus Bevacizumab versus Active Surveillance as Adjuvant Therapy in Patients with Hepatocellula… Ended
  2023-504303-86-00 Phase III 9 countries F. Hoffmann-La Roche AG
• The Sahlgrenska Anti-VEGF (SAHLVE) Study - a Prospective Randomized Double-blind Comparison of Bevacizumab and Aflibercept in Patients With … Ended
  2023-506317-22-00 Phase II 1 country Vaestra Goetalandsregionen
• REVOLUTION - Randomized phasE 2 study of Valproic acid in combination with bevacizumab and Oxaliplatin/fLUoropyrimidine regimens in patients… Ended
  2024-516844-25-01 Phase II 1 country IRCCS Istituto Nazionale Tumori Fondazione Pascale
• Clinical trial to compare the efficacy of two treatment sequencing schemes with chemotherapy (the regime called FOLFOX and FOLFIRI) in combi… Ended
  2024-510967-41-00 Phase III 2 countries Asociacion Grupo Tratamiento De Tumores Digestivos
• A clinical trial in patients with advanced liver cancer. The trial will investigate the safety, tolerability and clinical activity of durval… Ended
  2024-517085-41-00 Phase II 1 country AstraZeneca AB
• BEVERLY: A randomized open-label phase 3 trial comparing bevacizumab + erlotinib vs erlotinib alone as first line treatment of patients with… Ended
  2024-516843-15-00 Phase III 1 country IRCCS Istituto Nazionale Tumori Fondazione Pascale
• Biomarker discovery randomized phase IIb trial with carboplatin-cyclophosphamide versus paclitaxel with or without atezolizumaB as first-lin… Ended
  2024-516202-39-00 Phase II 1 country BOOG Study Center B.V.
• Multicenter randomized controlled trial of the value of intravitreal anti-VEGF injections as initial then adjuvant treatment in Coats' disea… Ended
  2024-517036-21-00 Phase II 1 country Fondation A De Rothschild
• A randomized, open label, multicenter phase II/III trial of sacituzumab govitecan compared to standard of care in metastatic, refractory col… Ended
  2023-509771-17-00 Phase II/III 1 country Universitaetsklinikum Heidelberg AöR
• Phase II study evaluating Holmium-166 TARE followed by maIntenance Therapy in liver limited unresectable colorectal cancer patients after fi… Ended
  2023-505356-22-00 Phase II 1 country Gruppo Oncologico Del Nord Ovest
• Randomized Phase 2 Study of DKN-01 Plus FOLFIRI/FOLFOX and Bevacizumab Versus FOLFIRI/FOLFOX and Bevacizumab as Second-line Treatment of Adv… Ended
  2022-501465-40-00 Phase II 1 country Leap Therapeutics Inc.
• A Study Evaluating the Efficacy and Safety of Neoadjuvant Immunotherapy Combinations in Patients with Surgically Resectable Hepatocellular C… Ended
  2022-502840-11-00 Phase I/II 4 countries F. Hoffmann-La Roche AG
• Oral fluorescent tracer administration to detect of early esophageal adenocarcinomas Ended
  2023-503801-12-00 Phase II 1 country University Medical Center Groningen
• A study to investigate response to ompenaclid combined with FOLFIRI plus bevacizumab in patients with advanced or metastatic colorectal canc… Ended
  2023-503356-27-00 Phase II 3 countries Inspirna Inc.
• FMT in IT-refractory HCC - FAB-HCC Pilot Study Ended
  2024-516835-29-00 Phase II 1 country Medical University Of Vienna
• A Phase 2, Randomized, Open-Label Study Evaluating the Safety and Efficacy of Magrolimab in Combination With Bevacizumab and FOLFIRI Versus … Ended
  2022-500177-13-00 Phase II 5 countries Gilead Sciences Inc.
• A clinical trial to investigate EO4010, a novel cancer vaccine therapy, with an immune checkpoint blocker, in patients with previously treat… Ended
  2023-509509-62-00 Phase I (FiH) 2 countries Enterome
• Clinical investigation evaluating safety and efficacy of selective intra-arterial 166Holmium radiation therapy in combination with atezolizu… Ended
  2024-511538-11-00 Phase II 1 country Institut Gustave Roussy
• Ezurpimtrostat autophagy inhibitor in association with Atezolizumab-Bevacizumab in first line treatment of unresectable hepatocellular carci… Ended
  2022-502078-17-00 Phase II 1 country Centre Hospitalier Universitaire De Grenoble
• Phase 1/2 study of Nivolumab and Relatlimab in Combination with Bevacizumab in First-line HCC Ended
  2024-510649-33-00 Phase I/II 5 countries Bristol Myers Squibb International Corporation

Showing 121–144 of 161 trials